C4 Therapeutics CEO Andrew Hirsch to present at J.P. Morgan Healthcare Conference on targeted protein degradation advancements.
Quiver AI Summary
C4 Therapeutics, Inc. (C4T), a clinical-stage biopharmaceutical company focused on targeted protein degradation science, announced that its CEO, Andrew Hirsch, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The presentation is scheduled for 2:15 pm PST and will be available via a live webcast on C4T’s website, with a replay accessible for two weeks afterward. C4T aims to create innovative medicines using its TORPEDO® platform to target and degrade disease-causing proteins, thereby improving treatment for challenging diseases and overcoming drug resistance. The company is progressing multiple oncology programs while expanding its research capabilities.
Potential Positives
- C4 Therapeutics will present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, which is significant for visibility and networking opportunities.
- The live webcast of the presentation allows for broader audience engagement, increasing potential interest from investors and stakeholders.
- C4 Therapeutics is advancing multiple targeted oncology programs, highlighting the company's commitment to innovation and addressing difficult-to-treat diseases.
- The announcement emphasizes C4T's unique TORPEDO® platform, showcasing their approach to overcoming challenges associated with drug resistance and undruggable targets.
Potential Negatives
- None
FAQ
What is the date and time of C4 Therapeutics' presentation at the J.P. Morgan Conference?
The presentation will occur on January 15, 2025, at 2:15 pm PST (5:15 pm EST).
How can I watch the C4 Therapeutics presentation live?
The presentation will be webcast live and can be accessed through C4T’s website on the Events & Presentations page.
Will there be a replay of the C4 Therapeutics presentation?
Yes, a replay of the webcast will be archived on the C4T website for at least two weeks after the presentation.
What is the focus of C4 Therapeutics' research?
C4 Therapeutics focuses on targeted protein degradation to develop new treatments for difficult-to-treat diseases.
Where can I find more information about C4 Therapeutics?
More information is available on C4 Therapeutics' official website at www.c4therapeutics.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CCCC Hedge Fund Activity
We have seen 65 institutional investors add shares of $CCCC stock to their portfolio, and 56 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ORBIMED ADVISORS LLC added 2,864,842 shares (+189.3%) to their portfolio in Q3 2024
- SOLEUS CAPITAL MANAGEMENT, L.P. added 2,552,000 shares (+63.0%) to their portfolio in Q3 2024
- BALYASNY ASSET MANAGEMENT L.P. removed 1,916,395 shares (-99.0%) from their portfolio in Q3 2024
- TCG CROSSOVER MANAGEMENT, LLC removed 1,276,574 shares (-100.0%) from their portfolio in Q3 2024
- MORGAN STANLEY added 1,188,196 shares (+104.4%) to their portfolio in Q3 2024
- POINT72 ASSET MANAGEMENT, L.P. added 923,268 shares (+331.4%) to their portfolio in Q3 2024
- WASATCH ADVISORS LP added 830,218 shares (+17.1%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that Andrew Hirsch, president and chief executive officer of C4T, will present at the 43
rd
Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PST (5:15 pm EST).
The presentation will be webcast live and may be accessed through C4T’s website on the
Events & Presentations page
. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is leveraging its TORPEDO
®
platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit
www.c4therapeutics.com
.
Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
